29.10.2014 • NewsBayern KapitalCunesoftFinanzierung

High Tech Gründerfonds (HTGF) and Bayern Kapital invest in Cunesoft GmbH

Cunesoft GmbH, a cloud software provider for regulatory document and submission management, specialized in the pharmaceutical industry, announced hat it successfully closed an investment round with High-Tech Gründerfonds and Bayern Kapital. The funds will be used to further internationalize sales activities as well as to expand the software's capabilities.

Within the pharmaceutical industry, the filing of the drug submission dossier involves critical and regulated processes. As the first European-based provider of a SaaS (Software as a Service) model Cunesoft now provides an integrated online regulatory software solution for effective submission document preparation as well as eCTD (electronic Common Technical Document) drug submission publishing.

"We are excited about having won High-Tech Gründerfonds and Bayern Kapital as investors", say Daniel Koppers and Rainer Schwarz. "The funding will allow us to include important collaborative features into the software. For example, a direct connection of the Cunesoft online platform with authority submission portals will be completed. Another area of functional expansion is the secure collaboration and sharing of our customers documents and dossiers with their external suppliers and customers."

 

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.